OverviewSuggest Edit

Nabriva is a clinical-stage biopharmaceutical company engaged in the research and development of novel antibiotics to treat serious infections, with a focus on the pleuromutilin class of antibiotics. Our goal is to become a fully integrated biopharmaceutical company focused on the research, development and commercialization of novel anti-infective products.

TypePublic
Founded2001
HQWien, AT
Websitenabriva.com

Latest Updates

Employees (est.) (Jan 2019)110(+25%)
Revenue (FY, 2018)$9.7 M
Share Price (Feb 2020)$1.6 (+4%)

Key People/Management at Nabriva Therapeutics

Denise Pollard-Knight

Denise Pollard-Knight

Director

Nabriva Therapeutics Office Locations

Nabriva Therapeutics has offices in Wien, King of Prussia, Dublin and Dublin 1
Wien, AT (HQ)
Leberstrasse 20
Dublin, IE
Alexandra House, The Sweepstakes
Dublin 1, IE
25 N Wall Quay, North Wall
King of Prussia, US
1000 Continental Dr #600
Show all (4)

Nabriva Therapeutics Financials and Metrics

Nabriva Therapeutics Revenue

Nabriva Therapeutics's revenue was reported to be $9.66 m in FY, 2018
USD

Revenue (Q3, 2019)

6.9m

Gross profit (Q3, 2019)

6.9m

Gross profit margin (Q3, 2019), %

99.8%

Net income (Q3, 2019)

(17.8m)

EBIT (Q3, 2019)

(17.2m)

Market capitalization (14-Feb-2020)

146.5m

Closing stock price (14-Feb-2020)

1.6

Cash (30-Sept-2019)

78.1m

EV

102.7m
Nabriva Therapeutics's current market capitalization is $146.5 m.
Annual
USDFY, 2016FY, 2017FY, 2018

Revenue

9.7m

EBIT

(55.0m)(73.8m)(114.4m)

EBIT margin, %

(1184%)

Interest expense

783.0k43.0k
Quarterly
USDQ1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Revenue

7.6m847.0k461.0k1.7m525.0k6.9m

Cost of goods sold

15.0k

Gross profit

6.9m

Gross profit Margin, %

100%
Annual
USDFY, 2016FY, 2017FY, 2018

Cash

32.8m86.8m102.0m

Prepaid Expenses

1.2m1.6m1.2m

Current Assets

90.6m93.8m108.8m

PP&E

519.0k1.3m1.1m
Quarterly
USDQ1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Cash

27.2m20.1m112.2m89.4m75.3m100.3m91.0m58.7m78.1m

Accounts Receivable

6.5m

Prepaid Expenses

903.0k1.4m1.5m1.0m1.2m1.2m973.0k1.4m1.2m

Inventories

162.0k
Annual
USDFY, 2016FY, 2017FY, 2018

Net Income

(54.9m)(74.4m)(114.8m)

Depreciation and Amortization

233.0k432.0k510.0k

Accounts Payable

(383.0k)2.6m(3.0m)

Cash From Operating Activities

(49.3m)(69.3m)(72.7m)
Quarterly
USDQ1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Net Income

(15.2m)(29.8m)(52.1m)(13.3m)(31.1m)(84.0m)(20.2m)(41.9m)(59.7m)

Depreciation and Amortization

76.0k149.0k295.0k133.0k262.0k391.0k125.0k245.0k162.0k

Inventories

(162.0k)

Accounts Payable

1.8m5.0m2.6m(1.4m)(2.2m)(1.5m)4.3m(346.0k)(39.0k)
USDY, 2019

EV/EBIT

-6 x

EV/CFO

-1.8 x

Debt/Equity

0.9 x

Debt/Assets

0.4 x

Financial Leverage

2.3 x
Show all financial metrics

Nabriva Therapeutics Acquisitions / Subsidiaries

Company NameDateDeal Size
Zavante Therapeutics IncJuly 25, 2018$124 m

Nabriva Therapeutics Online and Social Media Presence

Embed Graph

Nabriva Therapeutics News and Updates

Nabriva Therapeutics Announces $20 Million Registered Direct Offering

DUBLIN, Ireland and KING OF PRUSSIA, Pa., Dec. 20, 2019 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it has entered int…

Nabriva Therapeutics Provides Update on the Planned Resubmission of the New Drug Application for Intravenous CONTEPO™ (fosfomycin) for Injection

NDA resubmission anticipated early in the fourth quarter 2019 NDA resubmission anticipated early in the fourth quarter 2019

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Nabriva Therapeutics plc of Class Action Lawsuit and Upcoming Deadline - NBRV

NEW YORK, June 17, 2019 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Nabriva Therapeutics plc ("Nabriva" or the "Company") (NASDAQ: NBRV) and certain of its officers. The class action, filed in United States District Court, for the Southern...

Nabriva Therapeutics Reports First Quarter 2019 Financial Results and Recent Corporate Highlights

DUBLIN, Ireland, May 10, 2019 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the development of innovative anti-infective agents to treat serious infections, today announced its financial results for the three months ended March 31, 2019 and rec…

NABRIVA INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Nabriva Therapeutics plc To Contact The Firm

NEW YORK, May 6, 2019 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Nabriva Therapeutics plc ("Nabriva" or the "Company") (NASDAQ:NBRV). If you invested in Nabriva stock or options and would like to discuss your...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nabriva Therapeutics plc - NBRV

NEW YORK, May 1, 2019 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Nabriva Therapeutics plc ("Nabriva" or the "Company") (NASDAQ: NBRV). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 9980. The ...
Show more

Nabriva Therapeutics Blogs

Nabriva Therapeutics Receives FDA Acknowledgement of New Drug Application Resubmission for Intravenous CONTEPO™ (fosfomycin) for Injection

PDUFA action date set for June 19, 2020 DUBLIN, Ireland , Jan. 08, 2020 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a commercial-stage biopharmaceutical company engaged in the development of innovative anti-infective agents to treat serious infections, announced that the U.S.

Nabriva Therapeutics Resubmits New Drug Application for Intravenous CONTEPO™ (fosfomycin) for Injection

-Nabriva anticipates a six-month review period by the Food and Drug Administration -CONTEPO is a potential first-in-class intravenous antibiotic in U.S. for the treatment of complicated urinary tract infections DUBLIN, Ireland , Dec. 20, 2019 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:

Nabriva Therapeutics to Present at the 31st Annual Piper Jaffray Healthcare Conference

DUBLIN, Ireland and KING OF PRUSSIA, Pa. , Nov. 21, 2019 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that Gary Sender Chief

Nabriva Therapeutics Commends the CDC on the 2019 Antibiotic Resistance Threats Report, Highlighting the Need for New Antibiotics Aligned with Antibiotic Stewardship

S. pneumoniae continues to be designated by the CDC as “Serious Threat” underscoring need for rapid detection and prevention strategies, particularly in community setting   XENLETA™ has a novel mechanism of action that is different than all other antibiotics, has been shown to be associated with a

Nabriva Therapeutics Reports Third Quarter 2019 Financial Results and Recent Corporate Highlights

-More than 200 hospital formulary reviews of XENLETA™ scheduled before the end of the year- -Approximately 50% of all covered lives have outpatient formulary access to XENLETA- - Initiating focused community sales efforts for XENLETA- -Conference call today at 4:30 p.m.

Nabriva Therapeutics to Report Third-Quarter 2019 Financial Results on November 12, 2019

DUBLIN, Ireland , Oct. 31, 2019 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it will report its third-quarter 2019
Show more

Nabriva Therapeutics Frequently Asked Questions

  • When was Nabriva Therapeutics founded?

    Nabriva Therapeutics was founded in 2001.

  • Who are Nabriva Therapeutics key executives?

    Nabriva Therapeutics's key executives are Denise Pollard-Knight.

  • How many employees does Nabriva Therapeutics have?

    Nabriva Therapeutics has 110 employees.

  • What is Nabriva Therapeutics revenue?

    Latest Nabriva Therapeutics annual revenue is $9.7 m.

  • What is Nabriva Therapeutics revenue per employee?

    Latest Nabriva Therapeutics revenue per employee is $87.8 k.

  • Who are Nabriva Therapeutics competitors?

    Competitors of Nabriva Therapeutics include NovaBay Pharmaceuticals, LGC Biosearch Technologies and Keryx Biopharmaceuticals.

  • Where is Nabriva Therapeutics headquarters?

    Nabriva Therapeutics headquarters is located at Leberstrasse 20, Wien.

  • Where are Nabriva Therapeutics offices?

    Nabriva Therapeutics has offices in Wien, King of Prussia, Dublin and Dublin 1.

  • How many offices does Nabriva Therapeutics have?

    Nabriva Therapeutics has 4 offices.